MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. 2. The compound of claim 1 , wherein Ris independently cyclopropyl optionally substituted with C-Calkyl claim 1 , C-CalkoxyC-Calkyl claim 1 , —C(O)OH claim 1 , —C(O)NH claim 1 , or —C(O)O—C-Calkyl.3. The compound of claim 1 , wherein A is —(C═O)—O—R.4. The compound of claim 1 , wherein A is —(C═O)—R.5. The compound of claim 4 , wherein Ris optionally substituted aryl.6. The compound of claim 4 , wherein Ris optionally substituted heteroaryl.7. The compound of or claim 4 , wherein Z is —C-Calkyl containing 0 claim 4 , 1 claim 4 , 2 claim 4 , or 3 heteroatoms selected from O claim 4 , S claim 4 , or NRand substituted with one or more halo.8. The compound of wherein each of R claim 7 , R claim 7 , Rand Ris H.9. The compound of wherein one of R claim 7 , R claim 7 , Rand Ris halo.10. The compound of wherein two of R claim 7 , R claim 7 , Rand Rare halo.11. The compound of wherein one of Ror Ris halo.12. The compound of wherein Ris fluoro.13. The compound of wherein Ris fluoro.14. The compound of wherein Ris fluoro.15. The compound of wherein G is independently cyclopropyl optionally substituted with alkyl.16. The compound of wherein G is independently cyclopropyl optionally substituted with alkyl.17. The compound of wherein claim 1 ,{'sub': 2', '3, 'G is —NHS(O)—R;'}{'sup': '3', 'Ris independently cyclopropyl optionally substituted with alkyl;'}{'sup': '2', 'A is —(C═O)—R;'}{'sup': '2', 'Ris independently heteroaryl, or substituted heteroaryl;'}{'sub': 1', '8', 'i, 'Z is C-Calkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or ...

MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. 2. The compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , ester or prodrug thereof claim 1 , wherein R′ is H claim 1 , Y is N claim 1 , and wherein k=3 claim 1 , j=1 and L is absent.3. The compound of claim 2 , or a pharmaceutically acceptable salt claim 2 , ester or prodrug thereof claim 2 , wherein Ris hydrogen or halogen claim 2 , E is —NHS(O)— or —NHS(O)— claim 2 , and Ris cyclopropyl claim 2 , cyclobutyl claim 2 , cyclopentyl claim 2 , cyclohexyl claim 2 , cycloheptyl claim 2 , pyridinyl claim 2 , pyrimidinyl claim 2 , furanyl claim 2 , thienyl claim 2 , pyrrolyl claim 2 , pyrazolyl claim 2 , pyrrolidinyl claim 2 , morpholinyl claim 2 , piperidinyl claim 2 , piperazinyl claim 2 , or imidazolyl claim 2 , each of which is optionally substituted.4. The compound of claim 2 , or a pharmaceutically acceptable salt claim 2 , ester or prodrug thereof claim 2 , wherein J is —C(O)— and A is optionally substituted —C-Calkyl claim 2 , containing 0 claim 2 , 1 claim 2 , 2 claim 2 , or 3 heteroatoms selected from O claim 2 , S claim 2 , or N; optionally substituted aryl claim 2 , optionally substituted —C-Calkoxy claim 2 , optionally substituted heteroaryl claim 2 , optionally substituted —C-Ccycloalkyl claim 2 , or optionally substituted —C-Cheterocycloalkyl.5. The compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , ester or prodrug thereof claim 1 , wherein Y is —C(R″)— claim 1 , and R′ and R″ taken together with the carbon atoms to which they are attached form an aryl or heteroaryl ring claim 1 , each said ...

HCV Protease Inhibitors and Uses Thereof

This invention relates to: (a) compounds of formula I and salts thereof that, inter alia, are useful as hepatitis C virus (HCV) inhibitors; (b) intermediates useful for the preparation of such compounds and salts; (c) pharmaceutical compositions comprising such compounds and salts; and (d) methods of use of such compounds, salts, and compositions. 3. The compound or salt of claim 1 , wherein each Ris independently selected from the group consisting of carbocyclyl claim 1 , heterocyclyl claim 1 , alkylcarbonyl claim 1 , alkenylcarbonyl claim 1 , alkynylcarbonyl claim 1 , alkyloxycarbonyl claim 1 , alkenyloxycarbonyl claim 1 , alkynyloxycarbonyl claim 1 , carbocyclylcarbonyl claim 1 , heterocyclylcarbonyl claim 1 , carbocyclyloxycarbonyl claim 1 , heterocyclyloxycarbonyl claim 1 , aminoalkylcarbonyl claim 1 , carbocyclylaminocarbonyl claim 1 , heterocyclylaminocarbonyl claim 1 , carbocyclylalkyloxycarbonyl claim 1 , heterocyclylalkyoxycarbonyl claim 1 , alkylcarbocyclylsulfonyl claim 1 , and alkylheterocyclylsulfonyl claim 1 , wherein:the amino portion of the aminoalkylcarbonyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyloxycarbonyl, carbocyclylalkyloxycarbonyl, and heterocyclylalkyloxycarbonyl.4. The compound or salt of claim 1 , wherein each Ris independently selected from the group consisting of carbocyclyl claim 1 , heterocyclyl claim 1 , alkylcarbonyl claim 1 , alkyloxycarbonyl claim 1 , carbocyclylcarbonyl claim 1 , carbocyclyloxycarbonyl claim 1 , aminoalkylcarbonyl claim 1 , heterocyclylaminocarbonyl claim 1 , carbocyclylalkyloxycarbonyl claim 1 , and alkylcarbocyclylsulfonyl claim 1 , wherein:the amino portion of the aminoalkylcarbonyl optionally is substituted with one or two independently selected carbocyclylalkyloxycarbonyl.5. The compound or salt of claim 1 , wherein:{'sup': 8', 'B, 'Ris aminocarbonyl substituted with R; and'}{'sup': 'B', 'claim-text': the amino portion of the ...

MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. 114.-. (canceled)17. The method of claim 16 , wherein R′ is H claim 16 , Y is N claim 16 , and wherein k=3 claim 16 , j=1 and L is absent.18. The method of claim 17 , wherein Ris hydrogen or halogen claim 17 , E is —NHS(O)— or —NHS(O)— claim 17 , and Ris cyclopropyl claim 17 , cyclobutyl claim 17 , cyclopentyl claim 17 , cyclohexyl claim 17 , cycloheptyl claim 17 , pyridinyl claim 17 , pyrimidinyl claim 17 , furanyl claim 17 , thienyl claim 17 , pyrrolyl claim 17 , pyrazolyl claim 17 , pyrrolidinyl claim 17 , morpholinyl claim 17 , piperidinyl claim 17 , piperazinyl claim 17 , or imidazolyl claim 17 , each of which is optionally substituted.19. The method of claim 17 , wherein J is —C(O)— and A is optionally substituted —C-Calkyl claim 17 , containing 0 claim 17 , 1 claim 17 , 2 claim 17 , or 3 heteroatoms selected from O claim 17 , S claim 17 , or N; optionally substituted aryl claim 17 , optionally substituted —C-Calkoxy claim 17 , optionally substituted heteroaryl claim 17 , optionally substituted —C-Ccycloalkyl claim 17 , or optionally substituted —C-Cheterocycloalkyl.20. The method of claim 16 , wherein Y is —C(R″)— claim 16 , and R′ and R″ taken together with the carbon atoms to which they are attached form an aryl or heteroaryl ring claim 16 , each said ring is optionally substituted claim 16 , and wherein k=3 claim 16 , j=1 and L is absent.21. The method of claim 20 , wherein Ris hydrogen or halogen; E is —NHS(O)— or —NHS(O)— claim 20 , and Ris cyclopropyl claim 20 , cyclobutyl claim 20 , cyclopentyl claim 20 , cyclohexyl claim ...

MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. 2. The compound of claim 1 , wherein Ris independently cyclopropyl optionally substituted with C-Calkyl claim 1 , C-CalkoxyC-Calkyl claim 1 , —C(O)OH claim 1 , —C(O)NH claim 1 , or —C(O)O—C-Calkyl.3. The compound of claim 1 , wherein A is —(C═O)—O—R.4. The compound of claim 1 , wherein A is —(C═O)—R.5. The compound of claim 4 , wherein Ris optionally substituted aryl.6. The compound of claim 4 , wherein Ris optionally substituted heteroaryl.7. The compound of claim 5 , wherein Z is —C-Calkyl containing 0 claim 5 , 1 claim 5 , 2 claim 5 , or 3 heteroatoms selected from O claim 5 , S claim 5 , or NRand substituted with one or more halo.8. The compound of wherein each of R claim 7 , R claim 7 , Rand Ris H.9. The compound of wherein one of R claim 7 , R claim 7 , Rand Ris halo.10. The compound of wherein two of R claim 7 , R claim 7 , Rand Rare halo.11. The compound of wherein one of Ror Ris halo.12. The compound of wherein Ris fluoro.13. The compound of wherein Ris fluoro.14. The compound of wherein Ris fluoro.15. (canceled)16. (canceled)17. (canceled)18. A pharmaceutical composition comprising a therapeutically effective amount of a compound of or a pharmaceutically acceptable salt claim 1 , ester claim 1 , or prodrug thereof claim 1 , in combination with a pharmaceutically acceptable carrier or excipient.19. A method of treating a viral infection in a subject claim 1 , comprising administering to the subject a therapeutically effective amount of a compound of or a pharmaceutically acceptable salt claim 1 , ester or prodrug thereof.21. ...

Antiviral compounds

Un compuesto, un tautómero del compuesto, o una sal aceptable desde el punto de vista farmacéutico delcompuesto o tautómero, en donde el compuesto se selecciona del grupo que consiste en:un compuesto que tiene la Fórmula II:en donde:R6 se selecciona del grupo que consiste en hidrógeno y ciano;R8 se selecciona del grupo que consiste en hidrógeno y arilalquilo;R25 se selecciona del grupo que consiste en hidrógeno y alquilo;R37 se selecciona del grupo que consiste en hidrógeno, alquilo, hidroxialquilo, y cicloalquilo;R42 se selecciona del grupo que consiste en arilsulfanilo, heteroarilsulfanilo, y ariloxi; en donde R42 estásustituido en forma opcional con uno o más sustituyentes seleccionados en forma independiente de R46;R46 es uno o más sustituyentes seleccionados del grupo que consiste en hidrógeno, hidroxi, amino,halógeno, dialquilamino, y alcoxicarbonilamino;R70 se selecciona del grupo que consiste en arilo, y heterociclo; en donde R70 está sustituido en formaopcional con R75;R75 es uno o más sustituyentes seleccionados en forma independiente del grupo que consiste enhidrógeno, halógeno, alcoxi, ciano, alquilo, haloalquilo, y arilo.un compuesto que tiene la Fórmula III: A compound, a tautomer of the compound, or a pharmaceutically acceptable salt of the compound or tautomer, wherein the compound is selected from the group consisting of: a compound having Formula II: wherein: R6 is selected from the group consisting of hydrogen and cyano; R8 is selected from the group consisting of hydrogen and arylalkyl; R25 is selected from the group consisting of hydrogen and alkyl; R37 is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, and cycloalkyl; R42 is selects from the group consisting of arylsulfanyl, heteroarylsulfanyl, and aryloxy; wherein R42 is optionally substituted with one or more substituents independently selected from R46; R46 is one or more substituents selected from the group consisting of hydrogen, hydroxy, amino, halogen, dialkylamino, ...

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

Antiviral compounds

The present invention is directed to the use of compounds effective in inhibiting replication of Hepatitis C virus ("HCV") or other viruses, tautomers of said compounds, or pharmaceutically acceptable salts of said compounds or tautomers, for the manufacture of a medicament for the treatment of HCV.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

HEPATITIS C SERINA PROTEASAS MACROCICLIC INHIBITORS

La presente invención se relaciona con nuevos compuestos macrocíclicos y con métodos de uso de los mismos. La presente invenciôn también se relaciona con composiciones farmacéuticas que comprenden los compuestos de la presente invención, o las sales, ésteres o prodrogas farmacéuticamente aceptables, en combinación con un vehículo o excipiente farmacéuticamente aceptable.

Macrocyclic hepatitis c serine protease inhibitors

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

Macrocyclic hepatitis c serine protease inhibitors

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Phenanthridine macrocyclic hepatitis c serine protease inhibitors

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

INHIBITORS OF SERINE PROTEASE OF HEPATITIS C BASED ON FENANTRIDINE MACROCICILICS

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS Y MÉTODOS DE TRATAMIENTO DE UNA INFECCIÓN DE HEPATITIS C EN UN SUJETO EN NECESIDAD DE TAL TERAPIA CON DICHOS COMPUESTOS MACROCÍCLICOS MACROCÍCLICOS NOVEDOSOS. LA PRESENTE INVENCIÓN SE REFIERE ADEMÁS A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS DE LA PRESENTE INVENCIÓN, O SALES FARMACÉUTICAMENTE ACEPTABLES, ÉSTERES, O PROFÁRMACOS DE LOS MISMOS, EN COMBINACIÓN CON UN VEHÍCULO O EXCIPIENTE FARMACÉUTICAMENTE ACEPTABLE.

Macrocyclic hepatitis C serine protease inhibitors

Phenanthridine macrocyclic hepatitis c serine protease inhibitors.

La presente invención se refiere a compuestos macrocíclicos novedosos y a métodos para tratar infección de hepatitis C en un sujeto que necesita de la terapia con dichos compuestos macrocíclicos. La presente invención se refiere además a composiciones farmacéuticas que comprenden los compuestos de la presente invención, o sales, ésteres o profármacos farmacéuticamente aceptables de los mismos, en combinación con un transportador o excipiente.

MACROCYCLIC INHIBITORS OF SERINE PROTEASES OF HEPATITIS C

REFERIDO A COMPUESTOS DE FORMULA (I) O (I�) DONDE: J ESTA AUSENTE, O ES ALQUILENO OPCIONALMENTE SUSTITUIDO, C(O), S(C), S(O)2, S(O), ENTRE OTROS; A ES ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS OPCIONALMENTE SUSTITUIDOS; R1 SE SELECCIONA INDEPENDIENTEMENTE DE ARILO, HETEROARILO, HETEROCICLO, CARBOCICLO, OPCIONALMENTE SUSTITUIDOS, HALOGENO, ENTRE OTROS; G ES E-R5, DONDE E ES ESTA AUSENTE, O ES ALQUILENO, ALQUENILENO, ALQUINILENO OPCIONALMENTE SUSTITUIDOS ENTRE OTROS; R5 ES H, CARBOCICLO, HETEROCICLO, ARILO, OPCIONALMENTE SUSTITUIDOS ENTRE OTROS; R3 SE SELECCIONA INDEPENDIENTEMENTE DE ALQUILO, ALQUENILO, ALQUINILO OPCIONALMENTE SUSTITUIDOS ENTRE OTROS; L ESTA AUSENTE O SE SELECCIONA DE ALQUILENO, ALQUENILENO, ALQUINILENO OPCIONALMENTE SUSTITUIDOS; j ES 0, 1,2,3 O 4; k ES 0, 1, 2 O 3; m ES O, 1 O 2; n ES 0, 1, 2, 3, O 4; - - - DENOTA UNA UNION CARBONO-CARBONO SIMPLE O DOBLE; Y ES C(R"); R�Y R" TOMADOS JUNTO CON LOS ATOMOS DE CARBONO A LOS CUALES SE ENCUENTRAN UNIDOS FORMAN UN ANILLO ARILO O HETEROARILO. REFERIDO ADEMAS A UNA COMPOSICION FARMACEUTICA REFERRING TO COMPOUNDS OF FORMULA (I) O (I�) WHERE: J IS ABSENT, OR IS OPTIONALLY SUBSTITUTED ALKYLENE, C (O), S (C), S (O) 2, S (O), AMONG OTHERS; TO IS RENT, ALKENYL, ALKINYL, AMONG OTHERS OPTIONALLY SUBSTITUTED; R1 IS SELECTED INDEPENDENTLY OF ARYL, HETEROARIL, HETEROCICLO, CARBOCICLO, OPTIONALLY SUBSTITUTED, HALOGEN, AMONG OTHERS; G IS E-R5, WHERE E IS IS ABSENT, OR IS ALKYLENE, ALKYLENE, ALKYLENE OPTIONALLY SUBSTITUTED AMONG OTHERS; R5 IS H, CARBOCICLO, HETEROCICLO, ARYLUS, OPTIONALLY SUBSTITUTED AMONG OTHERS; R3 IS SELECTED INDEPENDENTLY OF ALKYL, ALKENYL, ALKINYL OPTIONALLY SUBSTITUTED AMONG OTHERS; L IS ABSENT OR SELECTED FROM ALKYLENE, ALKYLENE, ALKYLENE OPTIONALLY REPLACED; j IS 0, 1,2,3 O 4; k IS 0, 1, 2 O 3; m IS O, 1 O 2; n IS 0, 1, 2, 3, O 4; - - - DENOTES A SIMPLE OR DOUBLE CARBON-CARBON JOINT; Y ES C (R "); R� AND R" TAKEN TOGETHER WITH THE CARBON ATOMS TO WHICH THEY ARE UNITED TO MAKE AN ...

Phenanthridine macrocyclic hepatitis c serine protease inhibitors

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Phenanthridine macrocyclic hepatitis c serine protesea inhibitors

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

Phenanthridine macrocyclic hepatitis c serine protease inhibitors

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS

LA PRESENTE INVENCIÓN SE RELACIONA CON NUEVOS COMPUESTOS MACROCÍCLICOS Y CON MÉTODOS DE USO DE LOS MISMOS.LA PRESENTE INVENCIÓN TAMBIÉN SE RELACIONA CON COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS DE LA PRESENTE INVENCIÓN,O LAS SALES,ÉSTERES O PRODROGAS FARMACÉUTICAMENTE ACEPTABLES,EN COMBINACIÓN CON UN VEHÍCULO O EXCIPIENTE FARMACÉUTICAMENTE ACEPTBLES,EN COMBINACIÓN CON UN VEHÍCULO O EXCIPIENTE FARMACÉUTICAMENTE ACEPTABLE. THE PRESENT INVENTION IS RELATED TO NEW MACROCYCLIC COMPOUNDS AND TO THE METHODS OF USE OF THE SAME.THE PRESENT INVENTION IS ALSO RELATED TO PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THE COMPOUNDS OF THE PRESENT INVENTION, OR THE SALTS, PROJECTS IN A FARM PHARMACEUTICALLY ACCEPTABLE VEHICLE OR EXCIPIENT, IN COMBINATION WITH A PHARMACEUTICALLY ACCEPTABLE VEHICLE OR EXCIPIENT.

Anti-viral compounds

Disclosed is a pyrido[2,3-d]pyrimidin-4-yl compound, a tautomer of the compound, or a pharmaceutically acceptable salt of the compound or tautomer, wherein the compound has Formula I, wherein: W1, W2 and W3 are each N, and W4 is C(R33); Z is a bond, -CR41R41'- or -NR41-, wherein R41 and R41 ' are each independently selected from the group consisting of hydrogen, alkyl, alkenyl and alkynyl; A is a carbocyclyl or heterocyclyl, R10 is hydrogen or halogen; R17, R33 and R35, X, R22, R50 are defined in the specification, e.g. 4-(4-Amino-3-methyl-phenoxy)-N-(4-bromo-phenyl)-3-(7-isopropy-1-pyrido[2,3-d]pyrimidin-4-ylamino)-benzamide for the treatment of HCV infection.

Macrocyclic hepatitis C serine protease inhibitors

The present invention relates to novel macrocyclic compounds and methods of use thereof. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Anti-viral compounds

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

Macrocyclic hepatitis C serine protease inhibitors

Macrocyclic hepatitis c serine protease inhibitors

The present invention relates to novel macrocyclic compounds and methods of use thereof. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Macrocyclic hepatitis C serine protease inhibitors

Macrocyclic hepatitis c serine protease inhibitors

The present invention relates to novel macrocyclic compounds and methods of use thereof. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Macrocyclic hepatitis C serine protease inhibitors

Macrocyclic hepatitis c serine protease inhibitors

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Antivirale verbindungen

Macrocyclic hepatitis C serine protease inhibitors

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.